1. Home
  2. IFRX
  3. IFRX News

Latest InflaRx N.V. (IFRX) News on November 11, 2025

IFRX

MT Newswires

a day ago

InflaRx Says Phase 2a Data Support Further Development of INF904 in 2 Skin Conditions

IFRX

Associated Press Finance

a day ago

BC-Most Active Stocks

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
IFRX

GlobeNewswire

a day ago

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
IFRX

GlobeNewswire

4 days ago

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates
IFRX

Zacks

6 days ago

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
IFRX

Zacks

7 days ago

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
IFRX

GlobeNewswire

22 days ago

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

COVID’s remaining biotech contenders navigate a dwindling market
IFRX

Pharma Voice

5 months ago

COVID’s remaining biotech contenders navigate a dwindling market

IFRX

MT Newswires

5 months ago

Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating

IFRX

MT Newswires

5 months ago

Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13

IFRX

MT Newswires

5 months ago

Top Midday Decliners

IFRX

MT Newswires

5 months ago

InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
IFRX

GlobeNewswire

5 months ago

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

InflaRx to Participate in Upcoming Investor Conferences
IFRX

GlobeNewswire

6 months ago

InflaRx to Participate in Upcoming Investor Conferences

InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)
IFRX

Simply Wall St.

6 months ago

InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
IFRX

GlobeNewswire

6 months ago

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

InflaRx to Report First Quarter 2025 Results on May 7, 2025
IFRX

GlobeNewswire

6 months ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025

IFRX

MT Newswires

6 months ago

Cantor Fitzgerald Initiates InflaRx at Overweight $10 Price Target

Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?
IFRX

Insider Monkey

7 months ago

Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
IFRX

Zacks

8 months ago

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
IFRX

GlobeNewswire

8 months ago

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
IFRX

GlobeNewswire

8 months ago

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
IFRX

GlobeNewswire

8 months ago

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
IFRX

GlobeNewswire

9 months ago

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
IFRX

GlobeNewswire

9 months ago

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

IFRX

MT Newswires

9 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Friday

IFRX

MT Newswires

9 months ago

InflaRx Slumps Premarket After Pricing $30 Million Offering of Ordinary Shares, Pre-Funded Warrants

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
IFRX

GlobeNewswire

9 months ago

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
IFRX

GlobeNewswire

9 months ago

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch
IFRX

Simply Wall St.

9 months ago

Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
IFRX

GlobeNewswire

10 months ago

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS
IFRX

Pharmaceutical Technology

10 months ago

InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
IFRX

Zacks

10 months ago

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

IFRX

MT Newswires

10 months ago

InflaRx Gets Marketing Approval for COVID-19 Therapy in Europe

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
IFRX

GlobeNewswire

10 months ago

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

InflaRx Announces Participation in January Events in San Francisco
IFRX

GlobeNewswire

10 months ago

InflaRx Announces Participation in January Events in San Francisco

US Penny Stocks To Watch In December 2024
IFRX

Simply Wall St.

a year ago

US Penny Stocks To Watch In December 2024

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
IFRX

GlobeNewswire

a year ago

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?
IFRX

Insider Monkey

a year ago

Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?

IFRX

MT Newswires

a year ago

InflaRx Says Severe Covid Drug Gets EU Panel's Positive Opinion; Shares Rise Pre-Bell

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
IFRX

GlobeNewswire

a year ago

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Prenetics Global And 2 Other US Penny Stocks To Watch
IFRX

Simply Wall St.

a year ago

Prenetics Global And 2 Other US Penny Stocks To Watch

InflaRx Reports Q3 2024 Financial Results and Progress
IFRX

TipRanks

a year ago

InflaRx Reports Q3 2024 Financial Results and Progress

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
IFRX

Simply Wall St.

a year ago

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx expects cash to fund operations into 2026
IFRX

TipRanks

a year ago

InflaRx expects cash to fund operations into 2026

InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates
IFRX

Zacks

a year ago

InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
IFRX

GlobeNewswire

a year ago

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
IFRX

GlobeNewswire

a year ago

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
IFRX

GlobeNewswire

a year ago

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
IFRX

GlobeNewswire

a year ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

InflaRx Announces Participation in September Investor Events
IFRX

GlobeNewswire

a year ago

InflaRx Announces Participation in September Investor Events

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
IFRX

Zacks

a year ago

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
IFRX

GlobeNewswire

a year ago

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

InflaRx to Report Second Quarter 2024 Results on August 8, 2024
IFRX

GlobeNewswire

a year ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
IFRX

GlobeNewswire

a year ago

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases

IFRX

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

IFRX

MT Newswires

a year ago

Sector Update: Health Care Stocks Advance Monday Afternoon

IFRX

MT Newswires

a year ago

Sector Update: Health Care

IFRX

MT Newswires

a year ago

InflaRx Anti-Inflammatory Drug Chosen for Phase 2 Acute Respiratory Distress Syndrome Trial; Shares Rise

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
IFRX

GlobeNewswire

a year ago

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

InflaRx Hosts R&D Event Highlighting the Promise of INF904
IFRX

GlobeNewswire

a year ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
IFRX

GlobeNewswire

a year ago

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
IFRX

GlobeNewswire

2 years ago

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
IFRX

GlobeNewswire

2 years ago

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
IFRX

GlobeNewswire

2 years ago

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
IFRX

Zacks

2 years ago

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
IFRX

GlobeNewswire

2 years ago

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
IFRX

GlobeNewswire

2 years ago

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
IFRX

Simply Wall St.

2 years ago

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

InflaRx Appoints Jan Medina as Head of Investor Relations
IFRX

GlobeNewswire

2 years ago

InflaRx Appoints Jan Medina as Head of Investor Relations

Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher
IFRX

Zacks

2 years ago

Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher

Kopin Receives $1.4 Million Production Order For Specialized Weapon Sight Module
IFRX

Business Wire

2 years ago

Kopin Receives $1.4 Million Production Order For Specialized Weapon Sight Module

Planet Image International Limited Announces Closing of $5 Million Initial Public Offering
IFRX

PR Newswire

2 years ago

Planet Image International Limited Announces Closing of $5 Million Initial Public Offering

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
IFRX

GlobeNewswire

2 years ago

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

InflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutions
IFRX

Simply Wall St.

2 years ago

InflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutions

Bowman Awarded $1.9 Million in New Arizona Mining Contracts
IFRX

Business Wire

2 years ago

Bowman Awarded $1.9 Million in New Arizona Mining Contracts

D-Wave Announces 1,200+ Qubit Advantage2™ Prototype in New, Lower-Noise Fabrication Stack, Demonstrating 20x Faster Time-to-Solution on Important Class of Hard Optimization Problems
IFRX

Business Wire

2 years ago

D-Wave Announces 1,200+ Qubit Advantage2™ Prototype in New, Lower-Noise Fabrication Stack, Demonstrating 20x Faster Time-to-Solution on Important Class of Hard Optimization Problems

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
IFRX

Business Wire

2 years ago

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

IFRX

Business Wire

2 years ago

Tillys Announces Leadership Transition

Freshpet, Tilly’s, and More Stocks See Action From Activist Investors
IFRX

Barrons.com

2 years ago

Freshpet, Tilly’s, and More Stocks See Action From Activist Investors

Mega Matrix Corp. Appoints Xiangchen (Steven) Gao as Chief Operating Officer
IFRX

GlobeNewswire

2 years ago

Mega Matrix Corp. Appoints Xiangchen (Steven) Gao as Chief Operating Officer

American Public Education (APEI) Is Attractively Priced Despite Fast-paced Momentum
IFRX

Zacks

2 years ago

American Public Education (APEI) Is Attractively Priced Despite Fast-paced Momentum

Is American Public Education (APEI) Stock Undervalued Right Now?
IFRX

Zacks

2 years ago

Is American Public Education (APEI) Stock Undervalued Right Now?

Shareholders May Be More Conservative With Northern Technologies International Corporation's (NASDAQ:NTIC) CEO Compensation For Now
IFRX

Simply Wall St.

2 years ago

Shareholders May Be More Conservative With Northern Technologies International Corporation's (NASDAQ:NTIC) CEO Compensation For Now

Bassett Announces Regular Quarterly Dividend
IFRX

GlobeNewswire

2 years ago

Bassett Announces Regular Quarterly Dividend

Chatham Lodging Trust Announces Sale of Hotel
IFRX

Business Wire

2 years ago

Chatham Lodging Trust Announces Sale of Hotel

PetMeds® Announces new Chairman of the Board
IFRX

PR Newswire

2 years ago

PetMeds® Announces new Chairman of the Board

Ellington Residential Declares Monthly Common Dividend
IFRX

Business Wire

2 years ago

Ellington Residential Declares Monthly Common Dividend

Sangoma Named In The 2023 Gartner® Magic Quadrant™ For Unified Communications As A Service Report For Ninth Year
IFRX

Business Wire

2 years ago

Sangoma Named In The 2023 Gartner® Magic Quadrant™ For Unified Communications As A Service Report For Ninth Year

Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue
IFRX

GlobeNewswire

2 years ago

Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue

IFRX

ACCESSWIRE

2 years ago

iAccess Alpha Tax Loss Recovery Summit 2024 - Buyside Best Ideas January 9th-10th 2024

Bit Digital, Inc. Announces Monthly Production Update for December 2023
IFRX

PR Newswire

2 years ago

Bit Digital, Inc. Announces Monthly Production Update for December 2023

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
IFRX

GlobeNewswire

2 years ago

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Canaan Secures Follow-On Purchase Orders from Cipher and Stronghold
IFRX

PR Newswire

2 years ago

Canaan Secures Follow-On Purchase Orders from Cipher and Stronghold

CF BANKSHARES INC., PARENT OF CFBANK, NA, ANNOUNCES QUARTERLY CASH DIVIDEND.
IFRX

PR Newswire

2 years ago

CF BANKSHARES INC., PARENT OF CFBANK, NA, ANNOUNCES QUARTERLY CASH DIVIDEND.

Ellomay Capital Reports Results for the Three and Nine Months Ended September 30, 2023
IFRX

PR Newswire

2 years ago

Ellomay Capital Reports Results for the Three and Nine Months Ended September 30, 2023

A Look At The Intrinsic Value Of AMREP Corporation (NYSE:AXR)
IFRX

Simply Wall St.

2 years ago

A Look At The Intrinsic Value Of AMREP Corporation (NYSE:AXR)

Hemlo Explorers Announces Sale of Hawkins Gold Royalty
IFRX

GlobeNewswire

2 years ago

Hemlo Explorers Announces Sale of Hawkins Gold Royalty

Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock
IFRX

Zacks

2 years ago

Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock

7 Micro-Cap Stocks for Risk-Tolerant Investors to Buy in 2024
IFRX

InvestorPlace

2 years ago

7 Micro-Cap Stocks for Risk-Tolerant Investors to Buy in 2024

Share on Social Networks: